MCM
BMRN icon

MAI Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

MAI Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$389K Buy
6,805
+1,616
+31% +$88.5K ﹤0.01% 1439
2026
Q1 		$293K Buy
5,189
+4,380
+541% +$255K ﹤0.01% 1285
2025
Q4 		$48.1K Buy
809
+159
+24% +$8.66K ﹤0.01% 2030
2025
Q3 		$35.2K Sell
650
-41
-6% -$2.35K ﹤0.01% 2127
2025
Q2 		$38K Sell
691
-425
-38% -$25K ﹤0.01% 2014
2025
Q1 		$78.9K Sell
1,116
-400
-26% -$26.9K ﹤0.01% 1517
2024
Q4 		$99.6K Buy
+1,516
New +$102K ﹤0.01% 1442

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

MAI Capital Management's BMRN Position: Q2 2026 in Review

MAI Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 31% in Q2 2026, buying an estimated $88.5K and bringing the position to 6,805 shares worth $389K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

MAI Capital Management first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • MAI Capital Management held 6,805 shares of BioMarin Pharmaceuticals worth $389K as of Q2 2026.
  • MAI Capital Management bought 1,616 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $88.5K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1439 holding.
  • MAI Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.